Impact of Renin-angiotensin-aldosterone Blockade by Angiotensin-converting Enzyme Inhibitors or AT-1 Blockers on Frequency of Contrast Medium-induced Nephropathy: a Post-hoc Analysis from the Dialysis-versus-Diuresis (DVD) Trial
Overview
Nephrology
Affiliations
Background: After exposure to contrast medium (CM), about 10% of patients will develop contrast medium-induced nephropathy (CIN), with severe consequences for their prognosis. Although numerous studies evaluated risk factors for CIN development, it is still a matter of debate whether treatment with angiotensin-converting enzyme inhibitors (ACE-I) or AT-1 blockers increases the frequency of CIN after exposure to CM or not.
Methods: We performed a prospective, single-centre study (January 2001-July 2004) to compare different treatments for CIN prevention. Creatinine levels within 72 h after CM application and in-hospital outcomes were documented. The impact of RAAS blockade on the frequency of CIN was assessed retrospectively.
Results: Four hundred twelve patients were included (83.5% men, 29.1% diabetes mellitus, 74.6% hypertension). Of these, 269 patients (65.3%) were taking ACE-I (n = 236) or AT-1 blockers (n = 33). There were no significant differences in mean age (P = 0.075), creatinine levels (P = 0.113), gender (P = 0.281), diabetes mellitus (P = 0.172) or left ventricular ejection fraction (P = 0.09) between patients treated or not treated with RAAS blockade. Univariate analyses concerning development of CIN depending on treatment with RAAS blockade within 72 h found CIN to be significantly higher in patients treated with RAAS blockade (11.9 vs 4.2%, P = 0.006). Multivariate analyses (logistic regression) identified RAAS blockade to be an independent predictor of CIN (odds ratio 3.082, 95% confidence interval 1.234-7.698, P = 0.016).
Conclusion: Patients treated with RAAS blockade before exposure to CM develop significantly more often CIN within 72 h. Even after adjustment for confounding comorbidities, treatment with ACE-I or AT-1 blockers turned out to be an independent risk predictor.
Donmez E, Ozcan S, Sahin I, Okuyan E Adv Lab Med. 2023; 4(3):314-320.
PMID: 38075174 PMC: 10701481. DOI: 10.1515/almed-2023-0119.
Donmez E, Ozcan S, Sahin I, Okuyan E Adv Lab Med. 2023; 4(3):308-313.
PMID: 38075170 PMC: 10701494. DOI: 10.1515/almed-2023-0037.
Wasilewski M, Roy S, Patel N, Jovin I Am J Cardiovasc Drugs. 2020; 21(5):487-497.
PMID: 33369717 DOI: 10.1007/s40256-020-00455-5.
Davenport M, Perazella M, Yee J, Dillman J, Fine D, McDonald R Kidney Med. 2020; 2(1):85-93.
PMID: 33015613 PMC: 7525144. DOI: 10.1016/j.xkme.2020.01.001.
Wang W, Qu W, Sun D, Liu X J Renin Angiotensin Aldosterone Syst. 2020; 21(2):1470320320919587.
PMID: 32370685 PMC: 7227145. DOI: 10.1177/1470320320919587.